#TORNTPHARM | 🔮 ScoutQuest Crystal Ball
Future business outlook based on management commentary

Outlook: The company anticipates a full recovery in its insulin business by Q4 FY25 with additional revenue potential. BRL depreciation is expected to persist, with higher price increases sanctioned in Brazil. In Germany, progress is anticipated through enhanced tender wins from Q2 next year. In the US, gradual momentum is expected with new filings contributing significantly long-term. In India, the company aims to outperform market growth with a focus on market share, new launches, and consumer health expansion. The company plans to be net cash positive by FY27 and transition to a 25% tax rate by FY26. GLP-1 launches are planned in India and Brazil, with ongoing clinical trials.

Details:(ScoutQuest)

⚡ AI powered update byCheck-outto receive WhatsApp updates faster than twitter/X.
#TORNTPHARM